Serotonin 1A Agonists and Cognition in Schizophrenia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00178971

Enrollment

Registered

2005-09-15

Start date

2003-01-31

Completion date

2004-10-31

Last updated

2017-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizoaffective Disorder, Schizophrenia

Brief summary

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.

Detailed description

Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with olanzapine or risperidone for at least three months randomized to receive adjunctive treatment with a 5-HT1A agonist (buspirone, 15-30 mg/day)or placebo.

Interventions

DRUGadjunctive treatment with buspirone

buspirone 15-30 mg qd

DRUGplacebo

placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

Subjects must meet all of the following criteria to be eligible for participation in the current research study. 1. Subjects will be males and females between 18-65 years of age; 2. Subjects will have a definite diagnosis by DSM-IV criteria for Schizophrenia or Schizoaffective Disorder; 3. The subjects or their legal guardian must sign the informed consent; 4. Subjects currently being treated with olanzapine or risperidone for a duration of at least 3 months

Exclusion criteria

1. Subjects who are pregnant or lactating 2. Subjects who have brain damage and/or neurological disorders 3. Subjects who have current substance dependence 4. Subjects unable to provide informed consent

Design outcomes

Primary

Measure	Time frame
This study will examine the effect on cognition of the addition of buspirone compared with addition of a sugar pill to patients treated with olanzapine or risperidone	six weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026